# Endo receives FDA approval for sterile injectable facility in Indore, India

Endo announced that the U.S. FDA approved commercial production of VASOSTRICT at its new 20,000-square-foot aseptic manufacturing facility in Indore, India. The site increases sterile injectable capacity and is expected to begin production in 2026.

- Type: Expansion
- Announced: 2024-12-09
- Where: Indore, India, India
- Starts operating: 2026
- Status: announced
- Capacity: 20,000 square feet aseptic manufacturing facility
- Products: sterile injectable medicines, VASOSTRICT (vasopressin injection)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Endo](https://endata.com/companies/81616.md)

## Sources

- [investor.endo.com](https://investor.endo.com/2024-12-09-Endo-Receives-U-S-FDA-Approval-of-Manufacturing-Facility-in-Indore,-India), 2024-12-09: "The U.S. Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT at the company's newest aseptic manufacturing facility in Indore, India."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.